This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
TELLOMAK: T‐CELL LYMPHOMA ANTI‐KIR3DL2 THERAPY: AN OPEN LABEL, MULTI‐COHORT, MULTI‐CENTER, INTERNATIONAL PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF IPH4102 ALONE OR IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH ADVANCED T‐CELL LYMPHOMA. (12th June 2019)
Record Type:
Journal Article
Title:
TELLOMAK: T‐CELL LYMPHOMA ANTI‐KIR3DL2 THERAPY: AN OPEN LABEL, MULTI‐COHORT, MULTI‐CENTER, INTERNATIONAL PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF IPH4102 ALONE OR IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH ADVANCED T‐CELL LYMPHOMA. (12th June 2019)
Main Title:
TELLOMAK: T‐CELL LYMPHOMA ANTI‐KIR3DL2 THERAPY: AN OPEN LABEL, MULTI‐COHORT, MULTI‐CENTER, INTERNATIONAL PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF IPH4102 ALONE OR IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH ADVANCED T‐CELL LYMPHOMA